Matt Muscari

New Capabilities

As of September 2026: Leading US commercialization of SELUTION SLR

On September 21, the FDA approved the first sirolimus drug-eluting balloon for coronary use in the US. Cordis' SELUTION SLR expands inside a narrowed artery, releases sirolimus for up to 90 days, then is removed. No permanent implant stays behind.

Updated Sep 23